조건부 급여제도와 근거생성: 향후 제도 전략과 과제
Coverage With Evidence Development and Evidence Generation: Strategy and Good Practice for the Future
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The introduction of innovative medical technology requires changes in health technology assessment and coverage decision-making. The pace of medical technology development is accelerating, and existing entry criteria of coverage decision making need to change. Interest in coverage with evidence development (CED) policy is increasing in major countries. Since the 1990s, various CEDs have been operated by country (USA, UK, Australia, Japan, etc.). The objectives of this study reviews CED in the coverage decision-making process and examines current status of CED operations in Korea. In addition, we would like to review the issues that should be considered in operating the efficient CED in the future. This is a system that provides temporary benefits for new medical technologies when the evidence for the technologies is uncertain, and provides benefits for a certain period of time until the evidence is established. Also, it is a system that produces additional evidence to reduce uncertainty about clinical effectiveness and cost-effectiveness, and secures the potential effectiveness of technology and patient accessibility. The implementation process of CED in major countries has various conditions for each technology item. In generating evidence, the importance of the process of collecting research data, setting indicators, and deriving results is emphasized. It is important to establish guidelines for this process and specify the implementation process. Therefore, the conditional payment system requires a clear process for conducting research and monitoring. Currently, Korea is also operating a conditional selective benefit system, and it is necessary to prepare specific plans for the efficient implementation system and decision-making system related to conducting research to generate evidence, system operation, and evaluation processes.
Abstract
The introduction of innovative medical technology requires changes in health technology assessment and coverage decision-making. The pace of medical technology development is accelerating, and existing entry criteria of coverage decision making need to change. Interest in coverage with evidence development (CED) policy is increasing in major countries. Since the 1990s, various CEDs have been operated by country (USA, UK, Australia, Japan, etc.). The objectives of this study reviews CED in the coverage decision-making process and examines current status of CED operations in Korea. In addition, we would like to review the issues that should be considered in operating the efficient CED in the future. This is a system that provides temporary benefits for new medical technologies when the evidence for the technologies is uncertain, and provides benefits for a certain period of time until the evidence is established. Also, it is a system that produces additional evidence to reduce uncertainty about clinical effectiveness and cost-effectiveness, and secures the potential effectiveness of technology and patient accessibility. The implementation process of CED in major countries has various conditions for each technology item. In generating evidence, the importance of the process of collecting research data, setting indicators, and deriving results is emphasized. It is important to establish guidelines for this process and specify the implementation process. Therefore, the conditional payment system requires a clear process for conducting research and monitoring. Currently, Korea is also operating a conditional selective benefit system, and it is necessary to prepare specific plans for the efficient implementation system and decision-making system related to conducting research to generate evidence, system operation, and evaluation processes.
참고문헌 (19)
- Drummond M, "Coverage with evidence development for medical devices in Europe: can practice meet theory?", Health Econ, 31(Suppl 1), pp.179~194 (2022)
- Dawoud D., "Coverage with evidence development", Proceedings of the HTAi Annual Meeting in Adelaide Australia (2023), HTAi
- Myung JE, "Coverage with evidence development programs for medical technologies in Asia-pacific regions : a case study of Japan and South Korea", JMA J, 4, pp.311~320 (2021)
- Study for selective coverage policy, "Jo MW.", Health Insurance Review and Assessment Service, ~ (2023)
- "National coverage determinations with data collection as a condition of coverage: coverage with evidence development" (2006)[URL]
- "Medicare coverage database"[URL]
- Phillips KA, "CMS coverage with evidence development—challenges and opportunities for improvement", JAMA Health Forum, 3, pp.e223061~ (2022)
- "Technology appraisal data: appraisal recommendations"[URL]
- Abbvie JL, "Managed access: the Australian experience", Proceedings of the HTAi Annual Meeting in Adelaide Australia (2023), HTAi
- Research on follow-up management measures for pharmaceutical with risk sharing agreement, "Seoul National University", Health Insurance Review and Assessment Service, ~ (2016)
- Park S, "Evidence-based healthcare and the need of conditional decision", J Korean Med Assoc, 54, pp.1319~1329 (2011)
- Federici C, "Coverage with evidence development schemes for medical devices in Europe : characteristics and challenges", Eur J Health Econ, 22, pp.1253~1273 (2021)
- Garrison LP Jr, "Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force", Value Health, 16, pp.703~719 (2013)
- Reckers-Droog V, "Challenges with coverage with evidence development schemes for medical devices : a systematic review", Health Policy Technol, 9, pp.146~156 (2020)
- "Guidance for the public, industry, and CMS staff: coverage with evidence development" (2014)[URL]
- Trueman P, "Coverage with evidence development : applications and issues", Int J Technol Assess Health Care, 26, pp.79~85 (2010)
- Zeitler EP, "Coverage with evidence development : where are we now", Am J Manag Care, 28, pp.382~389 (2022)
- Hutton J, "Coverage with evidence development : an examination of conceptual and policy issues", Int J Technol Assess Health Care, 23, pp.425~432 (2007)
- "Conditional coverage and evidence development" (2023)[URL]